Wohltmann WE. JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study". J Am Acad Dermatol 2024 May 30:S0190-9622(24)00824.
PMID: 38823685